Case File
efta-02717489DOJ Data Set 11OtherEFTA02717489
Date
Unknown
Source
DOJ Data Set 11
Reference
efta-02717489
Pages
3
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From:
Sent:
Tuesday, March 11, 2014 11:46 PM
To:
Jeffrey Epstein
Subject:
FW: BMGF's Partnership with Global Good
Attachments:
GG Executive Summary- BMGF Internal Only.pdf; GG FAQ- BMGF Internal Only.pdf
LoweIls shop
From: Fil Randazzo
Sent: 3/=FD11/2014 3:20 PM
Subject: BMGF'= Partnership with Global Good
Dear Colleagues,
As the foundation's relationship manager for Globa= Good (GG) at Intellectual Ventures (IV), LLC., I would like to provide
yo= with some information which I hope will clarify questions that you may ha=e encountered. IV as some of you already
know is local company that works in intellectual property and invention. G=obal Good focuses on inventing technology
to improve the lives of the poor=in developing countries and their primary objective is to further charitab=e purpose.
Our collaboration with Global Good is a Co-chair priority.
Global Good is:
Managed by IV, leveraging IV's staff and resourcesc/=>
Funded by an investment from the Bill & Melinda Ga=es Asset Trust
Focused on inventing technology to improve lives of th= poor in developing countries
A for profit entity, whose primary objective is to adv=nce the mission of the foundation
EFTA_R1_02163299
EFTA02717489
Reinvesting their profits into GG to further the goals=of its charitable purpose
Holding quarterly brainstorming/collaboration sessions=with the BMGF on selected topics
Last year GG added a new Vice President and head, Ma=rizio Vecchione, and a new Director of Research and Strategy,
Ali Arjomand= Maurizio and Ali initiated a transformation of GG strategies and it= business model with six main
thematic areas of focus.
Disease Modeling
Vaccine logistics
Vector Management
Malaria and TB Diagnostics
Maternal and Child Health
Agricultural Productivity
These areas were chosen in part because they align w=th BMGF strategies, maximize GG's technical comparative
advantage and ha=e the highest potential impact. Recently, in order to increase efficiency =nd alignment within the
Global Good Fund different programs at IV have all been brought under the direct manag=ment of Maurizio Vecchione
(Global Good, New Horizons, Institute of Diseas= Modeling (formerly called EMOD) and the IV labs).
Given that we closely collaborate with GG on selecte= topics and projects of mutual interest, we want to encourage
collaboratio= and information exchange with GG. To help streamline and facilitate=the collaboration, we have an MOU
in place with GG that allows us to share with them selected grant proposals and ann=al reports. This allows them to
work with us in landscaping particular top=cs of mutual interest. However, we do need to ensure it is done appropriat=ly
and maintain confidentiality of any third party materials that have been provided to the foundation sub=ect to NDA
agreements. To this end, we have developed a process
chttp://operations/sites/ExecOfficeCollab/GGF/The%20Legal%20Corne=/GG%20Protocol%20to%20Share%20Grant%20
Proposals%20and%20ARs.docx> to share such materials. If you still have questions regarding =hat can and cannot be
shared from a legal perspective, please contact Alin= Flower in legal.
Global Good is holding monthly office hours at the f=undation (besides their individually scheduled ad hoc meetings).
Please check our BMGF Internal SharePoint Site for GG Information and Activities
<http://operatio=s/sites/ExecOfficeCollab/GGF/SitePages/Home.aspx?InitialTabld=Ribbon%2ER=ad&VisibilityContext=
WSSTabPersistence> for det=ils in case you want to casually stop by.
These resources are available should you want to lea=n more:
2
EFTA_R1_021 63300
EFTA02717490
GG Website <http://www.intellectualventures.com/index.p=p/globalgood>
o
BMGF Internal SharePoint Site for GG Information =nd Activities
chttp://operations/sites/ExecOfficeCo=lab/GGF/SitePages/Home.aspx?InitialTabld=Ribbon%2ERead&VisibilityCon=ext=
WSSTabPersistence>
o GG Executive Summary
chttp://operationsisites/ExecOfficeCollab/GG=iThe%20Legal%20Corner/GG%20Executive%20Summary-
%20BMGF%20Internal%200nly.p=f> (attached file)
o GG FAQ docum=nt <http://operations/sites/ExecOfficeCollab/GG=/The%20Legal%20Corner/GG%2OFAQ-
%20BMGF%20lnternal%20Only.pdf> (attached file)
o GG Office Hours
chttp://operat=onsisites/ExecOfficeCollab/GGF/The%20Legal%20Corner/GG%20Office%20Hours%20=t%20BMGF.pdf>
BMGF Extranet Site <https://portal.gatesfoundation.oresiteggl=balgood/clefault.aspx>
o Shared BMGF/GG site for Quarterly Brainstorming Sessio=s, etc.
We are excited about strengthening our partnership w=th GG and the contributions their unique skill sets bring to
tackling some=of our biggest challenges. It's critical that we foster a strong c=llaborative relationship with GG. Our
engagement will contribute to their success in leveraging their comparative advantage= to impact global health and
development. We look forward to the rol=s that all of you will play in continuing to strengthen the relationship.&=bsp;
Regards,
Fil
Fil Randazzo, Ph.D.
Deputy Director
Global Health Discovery & Translational Science
Bill & Melinda Gates Foundation
www.gatesfoundation.org
3
EFTA_R1_021 63301
EFTA02717491
Technical Artifacts (9)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Domain
www.gatesfoundation.orgPhone
2163299Phone
2717489Phone
2717490Phone
2717491URL
http://operatio=s/sites/ExecOfficeCollab/GGF/SitePages/Home.aspx?InitialTabld=Ribbon%2ER=ad&VisibilityContextURL
http://operations/sites/ExecOfficeCollab/GG=/The%20Legal%20Corner/GG%2OFAQURL
http://www.intellectualventures.com/index.p=p/globalgoodURL
https://portal.gatesfoundation.oresiteggl=balgood/clefault.aspxRelated Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.